What is Provista Diagnostics?
Provista Diagnostics is a pioneering biotechnology firm focused on the development of advanced diagnostic solutions for oncology. Its flagship innovation, Videssa Breast, represents a significant advancement in the field, serving as the first blood-based test designed to detect breast cancer in women with ambiguous or difficult-to-interpret mammographic findings. By utilizing a proprietary proteomics platform, the company identifies multiple tumor protein biomarkers, offering healthcare providers a more effective, data-driven approach to clinical assessment. This technology bridges the gap between initial imaging and definitive diagnosis, providing clarity where traditional methods may fall short. The company's market position is defined by its commitment to improving patient outcomes through high-accuracy, non-invasive diagnostic tools that integrate seamlessly into existing clinical workflows.
How much funding has Provista Diagnostics raised?
Provista Diagnostics has raised a total of $38.5M across 7 funding rounds:
Private Equity
$7.5M
Private Equity
$6M
Series B
$6M
Private Equity
$3.9M
Series A
$7.5M
Private Equity
$5.1M
Private Equity
$2.6M
Private Equity (2012): $7.5M, investors not publicly disclosed
Private Equity (2013): $6M, investors not publicly disclosed
Series B (2014): $6M, investors not publicly disclosed
Private Equity (2015): $3.9M featuring Groton Partners
Series A (2015): $7.5M, investors not publicly disclosed
Private Equity (2016): $5.1M with participation from MolecularMD Corp.
Private Equity (2016): $2.6M, investors not publicly disclosed
Key Investors in Provista Diagnostics
Groton Partners
Groton Partners is a merchant bank providing corporate financial advice and specialized investment opportunities, leveraging decades of experience in top-tier financial institutions.
MolecularMD Corp.
MolecularMD Corporation is a diagnostics firm specializing in precision medicine and oncology, focused on the development and commercialization of companion diagnostic tests.
What's next for Provista Diagnostics?
With the successful completion of this major enterprise-level funding round, Provista Diagnostics is well-positioned to accelerate the commercialization and clinical adoption of its diagnostic portfolio. The strategic allocation of this capital will likely focus on expanding the reach of Videssa Breast, enhancing its proteomics research capabilities, and strengthening its market presence within the competitive oncology diagnostics sector. As the company moves into its next phase of growth, the focus will remain on scaling operations to meet the increasing demand for precision medicine tools that offer both diagnostic confidence and improved patient care. Future milestones will likely involve further clinical validation studies and the potential expansion of its biomarker platform to address other oncology-related diagnostic challenges.
See full Provista Diagnostics company page
